PharmaTimesNews & Politicsnews

Compass Pathways reports six‑month data confirming durable profile of COMP360

Tuesday, July 7, 2026John PinchingView original

Second phase 3 trial shows sustained benefit and supports forthcoming regulatory submission

Read the full article on the original site.